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Abstract
Background: Ear disease is a major cause of preventable hearing loss and is very common in rural communities,
estimated to affect 1.3 million Australians. Rural community pharmacists are well placed to provide improved ear
health care to people who are unable to easily access a general practitioner (GP). The purpose of this study is to
apply an ear health intervention to the rural community-pharmacy setting in Queensland, Australia, to improve the
management of ear disease. The aims are the following: (1) to evaluate the feasibility, potential effectiveness and
acceptability of a community pharmacy-based intervention for ear health, (2) to evaluate the use of otoscopy and
tympanometry by pharmacists in managing ear complaints in community pharmacy and (3) to evaluate the
extended role of rural pharmacists in managing ear complaints, with the potential to expand nationally to improve
minor ailment management in rural communities.
Methods/design: This is a longitudinal pre- and post-test study of a community-pharmacy-based intervention with
a single cohort of up to 200 patients from two rural community pharmacies. Usual care practices pertaining to the
management of ear complaints will be recorded prior to the intervention for 8 weeks. The intervention will then be
piloted for 6 weeks, followed by a 12 month impact study. Patients aged > 13 years presenting to the pharmacies
with an ear complaint will be invited to participate. Trained pharmacists will conduct an examination including a
brief history, hearing screening, otoscopy and tympanometry assessments. Patients will be referred to a general
practitioner (GP) if required, according to the study protocol. Patients will complete a satisfaction survey and receive
a follow-up phone call at 7 days to explore outcomes including prescribed medications and referrals. Pharmacists
and GPs will complete pre- and post- intervention interviews. Patient, pharmacist and GP data will be analysed
using descriptive statistics and thematic analysis for the qualitative data.
Discussion: This study will demonstrate the implementation of a screening and referring ear health intervention in
rural community pharmacy. Feasibility, potential effectiveness and acceptability of the intervention will be assessed.
Trial registration: Australian and New Zealand Clinical Trial Registry Number: ACTRN12620001297910.
Keywords: Community pharmacy, Rural and remote, Pharmacy practice, Scope of practice, Ear
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Background
Ear care is recognised as important for the health of
the population [1]. Ear disease is increasing globally
with the World Health Organisation (WHO) propos-
ing that by 2050 we can expect 900 million people to
have disabling hearing loss, twice that of 2019 [2]. In
Australia, more than 1.3 million people are living with
a hearing condition that could have been prevented
[3]. In rural and remote communities, the prevalence
rate of middle ear diseases is as high as 50% in chil-
dren under 3 years of age, double the prevalence
recognised by WHO as a ‘massive public health prob-
lem’ [1, 2]. As well as the health consequences, un-
managed ear disease correlates with poor educational,
social and behavioural outcomes [1].
Access to trained health care providers and a lack of
infrastructure and supplies have been recognised as
major challenges to providing ear care internationally
[1]. There is currently a shortage of health care workers
in rural and remote communities able to provide ear
health care, which is predicted to worsen in the future
[4]. Despite these shortages, there have been a number
of innovative models of care developed to utilise consist-
ently accessible health care professionals such as phar-
macists to improve ear care [5]. A scoping review of
community pharmacist interventions in ear health iden-
tified eight studies, whereby pharmacists provided a tar-
geted ear health service, including hearing screening (4
in Australia), an otoscopy pilot study (1 in England) and
pharmacy-based ear clinics (1 in USA; 2 in England) [5].
Pharmacists are trusted and accessible health profes-
sionals, who are motivated to meet local community
needs [6]. Internationally, rural pharmacists are provid-
ing innovative models of care and working at expanded
scopes of practice to better meet health needs [7]. Phar-
macists, consumers and health professionals living in
rural and remote locations in Australia are supportive of
pharmacists expanding their service delivery to improve
patient outcomes [8–10]. Rural pharmacists in Australia
work in a unique setting with complex patients and lim-
ited access to health services and the potential for them
to improve ear health care is unknown. A new pilot
programme was developed to explore the impact of a
pharmacist ear care intervention on patient-related
outcomes.
Pilot and feasibility studies are an important step in
the development of successful interventions for health
[11]. There is emerging acknowledgement of the value
of pilot studies to better understand the conduct and ap-
plicability of an intervention to allow the results to be
better applied to patient care [11].
This paper describes the research protocol of the pilot,
LISTEN UP (Locally Integrated Screening and Testing
Ear aNd aUral Programme), a rural community
pharmacy-based intervention to improve the manage-
ment of ear health in the community in Australia.
Research aims
This study aims to: (1) explore the feasibility, potential
effectiveness and acceptability of a community
pharmacy-based intervention for ear health, (2) evaluate
the use of otoscopy and tympanometry by pharmacists
in managing ear complaints in community pharmacy
and (3) evaluate the extended role of rural pharmacists
in managing ear complaints, with potential to expand
nationally to improve ear care minor ailment manage-
ment in rural communities.
Methods and design
Study design and setting
This is a longitudinal pre- and post-design study of a
community-pharmacy-based intervention piloted in two
rural community pharmacies in Queensland, Australia.
Co-design has been applied to this study with stake-
holder, health professional, pharmacist and consumer
perspectives from previous research utilised in conjunc-
tion with community consultation to inform the design
of this study [8–10]. Prior to the intervention, participat-
ing pharmacies will collect usual care data for 8 weeks
beginning November 2020. The intervention will then
be piloted for 6 weeks at each pharmacy and then refine-
ment and improvements will be made before the longi-
tudinal impact study is conducted for 12 months.
Ethics approval
This project has been approved by the Human Research




Community pharmacies that meet the following criteria
are eligible to participate as a study site:
– Participating pharmacists must hold unconditional
registration with the Australian Health Practitioner
Regulation Agency (AHPRA) [12].
– Maintain accreditation standards for quality
assurance under the Quality Care Pharmacy
Programme (QCPP) [13].
– Have a private counselling area within the pharmacy
that is separated from the common pharmacy
counter, where one-to-one consultations can be
conducted.
– Have a high daily ‘walk-in customer’ number of
more than 100 customers per day.
– Have suitable information technology including a
computer with internet access, printer and scanner.
Taylor et al. Pilot and Feasibility Studies           (2021) 7:124 Page 2 of 8
– Are classified as rural or remote by the Modified
Monash Model classification system categories 4-7
[14].
– Are located in Queensland, Australia, due to
COVID-19 interstate restrictions around travel for
training.
Recruitment of pharmacies
Pharmacies who have participated in earlier research on
rural expanded pharmacy practice will be invited to ex-
press an interest to participate in the LISTEN UP. Those
pharmacies who are interested will be phoned by the
principal investigator to provide further explanation of
the study and obtain consent. Two pharmacies will be
enrolled in the study. Each pharmacy will be linked with
at least one participating general practitioner. An invita-
tion to participate with an information sheet and in-
formed consent form will be provided to each
pharmacist at the participating pharmacies and each GP
at the participating general practices.
Pharmacist training
Each participating pharmacist will undertake nationally
credentialed training in ear health including otoscopy
and tympanometry. This training will be mixed mode
with online and face-to-face components. The training
includes 55 h of online training and two full days of
workshops and is provided by the Benchmarque Group
[15]. The training will include the following units of
competencies: EHHPEH002—promote, educate and
manage ear health; EHHAEH001—assess ear health;
EHHPEA004—paediatric and TYMPTY001—perform
tympanometry.
Only pharmacists who have successfully completed the
required training will be eligible to participate in the
study. Completed certificates of training will be provided
to the principal investigator.
All training, including training materials will be con-
sistent with national standards and will be tailored to
suit the needs of community pharmacists. In addition,
pharmacists will be provided with a list of recommended
supplemental readings and resources. A member of the
research team who is a pharmacy academic will also pro-
vide face-to-face and virtual training to the pharmacists
on documentation processes for the project.
General practitioners (GPs)
General practitioner eligibility criteria
GPs that meet the following criteria are eligible to par-
ticipate in the study:
– Hold unconditional registration with the Australian
Health Practitioner Regulation Agency (AHPRA).
– Have capacity to provide timely appointments
(within 48 h) for participants referred to them for
review.
– Have suitable information technology provisions
including a computer with internet access, printer
and scanner.
– Are classified as rural or remote by the Modified
Monash Model classification system categories 4-7
[14].
– Are located in Queensland, Australia, due to
COVID-19 interstate restrictions around travel for
training.
Recruitment of GPs
At each pharmacy location, all GP practices within a 25-
km radius will be invited to participate in the study.
Participants
Sample size
The sample size was calculated using the formula n =
Z2P (1-P)/d2, where n=sample size, Z is the critical value
of the normal distribution at α/2 for a confidence level
of 95% where α is 0.05 and the critical value is 1.96, P =
expected prevalence or proportion = 0.14 (14%) and d =
precision = 0.05 (5%) [16]. To our knowledge, there is
no published community pharmacy-based ear health
interventions of similar nature, therefore no standard
reference could be applied to accurately determine
prevalence required to calculate the sample size. How-
ever, we have calculated a sample size based on data
from the Australian Government Department of Health,
which estimates 14% of Australians suffer from hearing
loss [3]. Therefore, n = 185 + 10% for missing data =
203 participants.
Given the calculated sample size, it is expected that
each of the two participating pharmacies would recruit
100 patients into the study during the impact study. The
duration of the project will be extended for up to 12
months to ensure adequate patient participant numbers
to power the study.
Recruitment of participants
Potential participants will be recruited from walk-in cus-
tomers who present at participating pharmacies seeking
advice or products for an ear complaint. Pharmacists will
invite these patients to participate in the study, provide
an information sheet (with verbal explanation), ensure
patient meets eligibility criteria and completes an in-
formed consent form. Informed consent obtained from
study participants is in written form.
Participant eligibility criteria
To be eligible for participation in the study, patients
must:
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– Be aged 13 years or older (to be able to
independently provide informed consent, those
between 13-16 years can consent for self or parent/
guardian may provide consent).
– Be able to understand the English language at a level
appropriate to provide informed consent
(pharmacists will use professional judgement to
determine if participants are able to provide
informed consent).
– Attend a participating pharmacy as a ‘walk-in’
customer seeking help for an ear complaint.
Patient will be excluded from the study if they:
– Are < 13 years old
– Have inadequate health literacy or English language
skills to provide informed consent
– Have obvious major trauma to the ear
– Are a high COVID-19 risk patient (e.g. travelled in a
COVID-19 hotspot within 14 days)
– Have not consented
Intervention participants
Participants' temperature will be measured in the waiting
area, if > 37.5 Celsius COVID-19 precautions will be im-
plemented and additional personal protection equipment
(PPE) applied, including face mask, gloves and face
shield. Pharmacists will conduct the consultation with
eligible consenting participants in a private consultation
space. Pharmacists will then document a brief history of
the ear complaint including symptoms, duration and
treatments tried by the patient on a template service
summary document (Appendix 1) provided to them.
Pharmacists will then examine the ears using otoscopy
and tympanometry. If the complaint is hearing related,
pharmacists will perform a hearing screening test using
the Sound Scouts application [17]. Sound Scouts is an ap-
plication based hearing check that can be used in per-
sons over the age of 4 years to detect conductive hearing
loss, sensorineural hearing loss and difficulties listening
in noise [17].
Equipment
The otoscope used in this study is the MedRx video oto-
scope. The tympanometer is the Amplivox Otowave 102.
Hearing screening will be conducted using the Sound
Scouts application with Senheiser HD 300 headphones.
Patient data collection
Patient data collected includes full name, postcode, age,
gender, allergies, medicines, medical conditions, preg-
nancy/breastfeeding status, temperature, brief history of
the ear complaint including symptoms, duration and
treatments tried by the patient, otoscopy, tympanometry
and hearing screening findings/results. This information
will be documented on the service summary record. This
record will contain all the information collected by the
pharmacists from the patient consultation. It was devel-
oped in consultation with an advisory group (consisting
of stakeholder representatives from various organisations
in the health sector), is formatted in Microsoft Office
and is stored on a password protected hard drive.
Protocol
Pharmacists will follow a protocol to determine the
pathway (Fig. 1) for the patient. If otoscopy and tympa-
nometry assessments are normal and hearing is not af-
fected, the pharmacist may recommend no treatment
and advise patient to monitor and seek medical advice if
condition does not improve or worsens. If otoscopy indi-
cates excessive wax only or moisture retention from
water activity only and no other symptoms are present,
the pharmacist may recommend pharmacy products in-
cluding ear drops containing drying agents or wax dis-
solvents. All other patients will be referred to a GP with
an appointment made by the pharmacist before they
leave the pharmacy. Pharmacists will be able to book ap-
pointments with the GPs via a public online booking
platform or via telephoning the GP practice. If the
pharmacist is unable to make a timely appointment with
a GP, the patient will be recommended to attend the
local emergency department. Participants will be asked
to complete a patient satisfaction survey and consent to
a follow-up phone call in 7 days.
GP referral
The GP to which the patient has been referred will be
emailed a password encrypted file with all of the patient
data including temperature, brief history of the ear com-
plaint including symptoms, duration and treatments
tried by the patient, otoscopy, tympanometry and hear-
ing screening findings/results.
Pharmacist recommendations
Pharmacists will be asked to record their actual recom-
mendations and recommendations they would have
made if they had an expanded scope including if they
would have recommended a prescription medicine or re-
ferral to other service providers including audiometrists,
speech pathologists, or ear, nose and throat specialists.
This information will be collected for research purposes
only as current practice does not allow Australian phar-
macists to recommend prescription medicines or refer
patients to specialty services.
Follow-up
A member of the research team will phone all patient
participants 7 days after their pharmacy consultation to
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explore the patient outcomes from the intervention. Pa-
tients will be asked about the condition of their ear com-
plaint (improvement/deterioration), their satisfaction
with the pharmacy intervention (Likert scale), if they
were referred to a GP, if they attended the GP appoint-
ment and what advice, prescription or referral they had
received from the GP. If the patient indicates further de-
terioration of the condition, a lack of improvement or a
concern about the complaint, the researcher will offer to
refer the patient to the GP and/or advise the patient to
seek further medical advice.
Data saturation
Total population sampling will be conducted in this
study. We will attempt to interview all GPs and pharma-
cists by inviting them to participate in an interview three
times. In addition, all participants will receive a follow-
up phone call four times, including at least one out of
Fig. 1 LISTEN UP study protocol pathway
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normal business hours, in an attempt to ensure as many
as possible participants receive the follow-up phone call.
Study measurements and outcomes
Data pertaining to patient, pharmacist and GP experi-
ences of the ear health intervention will be collected
via semi-structured interviews pre- and post- inter-
vention with pharmacists and GPs, service summary
documentation, patient satisfaction surveys and 7-day
follow-up interviews with patients. These data collec-
tion tools were developed in house to suit this in-
novative model. Pharmacist and GP interviews will
include questions pertaining to perceptions of ex-
panded pharmacy services, current local landscape of
ear health (incidence, access to services) and ex-
pected/actual outcomes of the LISTEN UP project in-
cluding pharmacist capacity, patient receptiveness and
GP/pharmacist/patient interaction. Usual care data
will be recorded for 8 weeks prior to the intervention.
The usual care data will include a non-identifiable
record of ear complaints presenting to the pharmacy,
the description of the complaint and the pharmacists
recommendations (Table 1).
Usual care data will record patient age groups, type of
complaint (ear pain, ear wax, swimmers ear, ear itch,
hearing loss or other), duration of the complaint,
pharmacist recommendations (pharmacy products, ver-
bal GP referral, verbal emergency department referral or
other).
Initial study measurements are pharmacist and GP
perspectives of ear health in the community, this de-
scribed study protocol, expected outcomes, and antici-
pated enablers and barriers. This data will be collected
prior to the study beginning via semi-structured inter-
views to explore the expected feasibility of the study.
The interviews will be repeated post-study and the data
collected from pre-intervention will be compared with
data collected from these interviews to measure a change
of opinion with pharmacists and GPs post-intervention.
Pharmacists will record the consultation data on a ser-
vice summary document (Appendix 1). This document
will also collect pharmacist recommendations for the pa-
tient, including they would have made if they had an ex-
panded scope of practice such as prescription medicines
and specialist referrals. This data will be compared with
data provided by the patients at the 7-day follow-up
phone call about the medicines they were prescribed
and any referrals they may have received. In addition,
qualitative data relating to the patient experience of the
pharmacy service and patient perceived outcomes of the
ear complaint will be collected during the patient
interviews.
Study measurements
The study measurements collected in the intervention
include pharmacist views, pharmacist recommendations,
GP views and patient views. There measurements are
aligned to the primary and secondary outcomes of the
study (Table 2).
Study outcomes
The outcomes of this study will be assessed against the
objective of implementing a rural community pharmacy-
based ‘model of care’ to improve the management of ear
complaints in the community.
Primary
(1) To evaluate the feasibility, acceptability and
potential effectiveness of a community pharmacy-
based intervention for ear health by exploring:
a. Pharmacist views of:
i. Pharmacist capacity and competence to
provide the intervention (motivation,
confidence, competence, experience of
training, capacity (workflow/workload))
ii. Patient acceptance
iii. Pathway to GP service (timeliness of
appointment, GP staff attitudes)
b. Patient views of the service in terms of access,
alternative health care options, satisfaction and
willingness to pay (confidence/acceptance of
pharmacist service, referral process, timeliness
of pharmacists consult/GP consult).
c. GP views on appropriateness of pharmacist
referrals, collaborative care with pharmacists
(use of telehealth).
(2) To evaluate the use of otoscopy and tympanometry
by pharmacists to improve specificity of ear
condition management in community pharmacy by
comparing:
a. Usual care data with intervention data
pertaining to pharmacist recommendations.
b. Pharmacist recommendations on the patient
service summary record compared to GP
Table 1 Data collection methods for pre-, during and post-intervention phases
Patients Pharmacists General practitioners
Pre-intervention Record of usual care in pharmacy for 8 weeks Semi-structured interview Semi-structured interview
During intervention Patient satisfaction survey Service summary document
Post-intervention Semi-structured interview (7-day follow-up) Semi-structured interview Semi-structured interview
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prescriptions and referrals described by patients
at the 7-day follow-up phone call.
c. Patient acceptance of pharmacists performing
examinations with an otoscope and
tympanometer.
Secondary
1) To evaluate the extended role of rural community
pharmacists in managing ear complaints as a minor
ailment in the community by evaluating, patient,
GP and pharmacist perspectives of a community
pharmacy-based ear health pre- and post-
intervention.
2) To evaluate the potential for implementation of a
national model of community pharmacy-based in-
terventions to improve the management of minor
ailments in rural communities.
3) To provide evidence to guide the scheduling of
medicines to allow pharmacists to better manage
minor ailments in community pharmacies.
Data analysis
Data collected via semi-structured interviews will be
transcribed verbatim and thematically analysed both in-
ductively and deductively, using the NVivo 12 software
programme [18, 19]. Data collected from the patient sur-
veys and patient service summary record will be ana-
lysed using descriptive statistics and frequencies using
IBM SPSS Statistics 25 for Windows.
Discussion
The protocol and methods outlined will inform the de-
velopment of an intervention framework for managing
multiple minor ailments in the rural community phar-
macy setting in Queensland, Australia. Positive out-
comes from this study may demonstrate feasibility,
potential effectiveness and acceptability of such an inter-
vention. Internationally, expanded practice is becoming
a common practice and is widely accepted in many
countries; however, evidence to support expanded
models of care in rural settings both internationally and
in Australia are exceptionally limited and thus this
protocol will add to the evidence base [7].
Preliminary discussions with professional pharmacy as-
sociations and professional indemnity insurers have been
conducted and there is a high level of support for this
programme.
Limitations of the study protocol
This is a small pilot study of a complex intervention, with
no control group. If the pilot testing indicates feasibility and
effectiveness of this intervention, it will be important to val-
idate the study with larger numbers in varied locations with
a control group to comprehensively determine effectiveness
and scalability. In addition, it was deemed out of scope for
the small scale pilot protocol to include an economic evalu-
ation of the study and thus a larger study would be required
to examine economic sustainability.
Conclusions
Ear disease is recognised as a major public health con-
cern for rural and remote communities, especially due to
accessibility of health professionals, requiring innovative
strategies for effective management. Patients with ear
complaints regularly present to community pharmacies
seeking help due to difficulty in accessing GPs outside of
metropolitan locations. Currently, pharmacists provide
recommendations based on symptomatic descriptions of
ear complaints provided by patients. Pharmacists are in
an appropriately positioned location to provide im-
proved ear care and are well placed to ensure patients
are able to access timely health care. To our knowledge,
this is the first community pharmacy-based study pro-
viding a specific ear health intervention in rural phar-
macy practice to enable a pharmacist to improve the
management of ear complaints.
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